Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of NIBRG-14 H5N1 mock-up vaccine in healthy adults in Hungary
2005-004153-10Phase 4Completed
- Sponsor
- OTH Therapeutics
- Start
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of NIBRG-14 H5N1 vaccine in Influenza A H5N1 infection (H5N1), sponsored by OTH Therapeutics. Primary endpoint: Seroconversion rate at day 21–28 after immunization. Started Mar 2006; status: completed.
02
Drugs
NIBRG-14 H5N1 vaccine
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on 2005-004153-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004153-10.